GlassScriptPhysician profile
Andrea Semones
NPI 1932539053
$3,032.93
in general payments reported to CMS, 2019-2025
18 companies · $1,053 in 2025
The $1,053 reported for 2025 was more than what 81% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $381 · 2022: $316 · 2023: $302 · 2024: $980 · 2025: $1,053.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $791.22 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $483.05 | 2021-2025 | Rexulti, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $455.45 | 2021-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $270.87 | 2022-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $229.47 | 2021-2025 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $199.14 | 2024-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $117.60 | 2024-2025 | Ingrezza |
| Alkermes, INC. | $109.97 | 2021-2025 | Lybalvi |
| Lundbeck LLC | $76.98 | 2022-2023 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $62.69 | 2025 | Uzedy |
| Supernus Pharmaceuticals, INC. | $42.70 | 2023-2025 | Qelbree, Qelbree |
| Collegium Pharmaceutical, INC. | $39.95 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $35.86 | 2021 | |
| Tris Pharma INC | $34.46 | 2024 | Dyanavel Xr |
| Noven Therapeutics, LLC | $31.08 | 2024-2025 | Xelstrym |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $24.44 | 2024 | Loreev Xr |
| Lilly USA, LLC | $14.29 | 2024 | Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $13.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Semones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.